| Date | Title | Description |
| 01.09.2026 | Enhertu approved in EU for 1L HER2-positive mBC | Enhertu approved in EU for 1L HER2-positive mBC
Tue, Sep 01, 2026 08:30 CET Report this content
01 September 2026
Enhertuplus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients wi... |
| 01.09.2026 | AstraZeneca completes agreement for Zegfrovy | AstraZeneca completes agreement for Zegfrovy
Tue, Sep 01, 2026 08:05 CET Report this content
01 September 2026
AstraZeneca completes global license agreement
for oral EGFR inhibitor Zegfrovy for lung cancer
AstraZeneca today announced the s... |
| 01.09.2026 | Tagrisso + Orpathys improved PFS in 1L EGFRm lung | Tagrisso + Orpathys improved PFS in 1L EGFRm lung
Tue, Sep 01, 2026 08:00 CET Report this content
1 September 2026
Tagrisso plusOrpathysdemonstrated statistically significant and highly clinically meaningful improvement in progression-free ... |
| 31.08.2026 | AAX Biotech Enters Next Phase of Collaboration with Daiichi Sankyo Following Initial Evaluation of Opti-mAb® Technology | AAX Biotech Enters Next Phase of Collaboration with Daiichi Sankyo Following Initial Evaluation of Opti-mAb® Technology
Mon, Aug 31, 2026 07:45 CET Report this content
Swedish biotech company AAX Biotech AB today announced that its research... |
| 24.08.2026 | Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization | - |
| 17.08.2026 | Enhertu improved PFS in 1L HER2m lung cancer | Enhertu improved PFS in 1L HER2m lung cancer
Mon, Aug 17, 2026 08:30 CET Report this content
17 August 2026
Enhertu demonstrated statistically significant and clinically meaningful improvement in
progression-free survival as 1st-line treatm... |
| 17.08.2026 | Tagrisso+Orpathys improved PFS & OS in EGFRm lung | Tagrisso+Orpathys improved PFS & OS in EGFRm lung
Mon, Aug 17, 2026 08:00 CET Report this content
17 August 2026
Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful
improvements in progression-free an... |
| 13.08.2026 | Tenosynovial Giant Cell Tumor Treatment Market to Witness Robust Growth Driven by Precision Medicine and Targeted Oncology Innovation | Overview
According to DataM Intelligence, the global tenosynovial giant cell tumor treatment market size reached USD 8.88 billion in 2025 and is forecast to reach USD 13.40 billion by 2035, expanding at a CAGR of 4.2% during the 2026–2035 f... |
| 31.07.2026 | Datroway approved in EU for TNBC | Datroway approved in EU for TNBC
Fri, Jul 31, 2026 08:48 CET Report this content
31 July 2026
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic T... |
| 18.07.2026 | Nvidia Drives Physical AI Revolution in Japan | Nvidia launched Cosmos 3 Edge. This new AI model reshapes real-time physical interaction. It moves artificial intelligence beyond data centers. The focus is now factories, hospitals, and warehouses. CEO Jensen Huang spearheaded this push in... |
| 16.07.2026 | Nvidia unveils new AI model and expands Japan’s physical AI ecosystem | Nvidia introduced its new AI model Cosmos 3 Edge.
The company plans to expand physical AI ecosystem in Japan with local partners.
It will also collaborate with local companies in the healthcare sector.
Nvidia unveiled a new artificial intel... |
| 16.07.2026 | Nvidia launches Cosmos 3 Edge AI model to power robots and vision AI, expands Japan robotics and physical AI push | Nvidia has launched Cosmos 3 Edge, a new AI model built to help robots and vision-based AI agents interpret and respond to physical environments in real time.
The release marks the latest step in Nvidia’s effort to move artificial intellige... |
| 15.07.2026 | AstraZeneca Licenses Zegfrovy From Dizal In Deal Worth Up To $1.5 Billion | AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical for Zegfrovy, an oral targeted therapy approved in the U.S. and China for certain patients with non-small cell lung cancer.
Under the agreement, ... |
| 14.07.2026 | AstraZeneca licenses novel EGFR inhibitor | AstraZeneca licenses novel EGFR inhibitor
Tue, Jul 14, 2026 08:00 CET Report this content
14 July 2026
AstraZeneca enters exclusive global license agreement for novel oral
EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
Co... |
| 14.07.2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| 29.06.2026 | Enhertu approved in EU for HER2+ solid tumours | Enhertu approved in EU for HER2+ solid tumours
Mon, Jun 29, 2026 08:41 CET Report this content
29 June 2026
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously t... |
| 29.06.2026 | Datroway recommended for approval in EU for TNBC | Datroway recommended for approval in EU for TNBC
Mon, Jun 29, 2026 08:00 CET Report this content
29 June 2026
Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast canc... |
| 27.05.2026 | US FDA decision date on camizestrant extended | US FDA decision date on camizestrant extended
Wed, May 27, 2026 08:00 CET Report this content
27 May 2026
US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data
The US Food and Drug Administrat... |
| 26.05.2026 | Enhertu recommended in EU for HER2+ solid tumours | Enhertu recommended in EU for HER2+ solid tumours
Tue, May 26, 2026 08:00 CET Report this content
26 May 2026
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours
Bas... |
| 26.05.2026 | Camizestrant recommended for breast cancer in EU | Camizestrant recommended for breast cancer in EU
Tue, May 26, 2026 08:00 CET Report this content
26 May 2026
Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive br... |
| 26.05.2026 | Datroway approved in US for 1L triple-negative BC | Datroway approved in US for 1L triple-negative BC
Tue, May 26, 2026 08:00 CET Report this content
26 May 2026
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic tri... |
| 18.05.2026 | Enhertu approved in two HER2+ early BC settings | Enhertu approved in two HER2+ early BC settings
Mon, May 18, 2026 08:05 CET Report this content
18 May 2026
Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
Approved for use before surge... |
| 06.05.2026 | Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program | Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 19.02.2026 | AAX Biotech secures investment from Trio Impact Invest | AAX Biotech secures investment from Trio Impact Invest
Thu, Feb 19, 2026 06:30 CET Report this content
Biotech company AAX Biotech, a leading innovator in technologies for antibody-based medicines, today announced that Trio Impact Invest AB... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 29.01.2026 | Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" | HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-dep... |
| 21.01.2026 | Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology | Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines
TORONTO, Jan. 21, 2026 /PRNewswire/ -- Daiichi Sankyo (TSE: 4568) has further established its presence in Canada wit... |
| 08.01.2026 | Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway | Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated fo... |
| 29.12.2025 | Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy | TAIPEI and SAN DIEGO, Dec. 29, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging... |
| 16.12.2025 | Enhertu approved in US for 1L HER2+ metastatic BC | Enhertu approved in US for 1L HER2+ metastatic BC
Tue, Dec 16, 2025 08:00 CET Report this content
16 December 2025
Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER... |
| 15.12.2025 | Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AI | What You Should Know:
– Lunit has announced a collaboration with pharmaceutical giant Daiichi Sankyo to integrate its AI-powered Lunit SCOPE digital pathology products into two of Daiichi Sankyo’s oncology pipeline programs.
– The partnersh... |
| 15.12.2025 | Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research | Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs
SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a l... |
| 30.10.2025 | Innovent’s tie-up with Takeda tests investor faith in China’s biotech dream | Since early October, shares of China’s innovative drugmakers have trended downward. As investors quipped about the need for another major deal to restore confidence, one such event finally arrived.
On October 22, Innovent Biologics announce... |
| 22.10.2025 | AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-Generation Antibody Therapeutics | AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-Generation Antibody Therapeutics
Wed, Oct 22, 2025 08:55 CET Report this content
Stockholm, Sweden, Oct 22, 2025 – Swedish biotech company AAX ... |
| 06.10.2025 | Datroway improved OS and PFS in TROPION-Breast02 | Datroway improved OS and PFS in TROPION-Breast02
Mon, Oct 06, 2025 08:30 CET Report this content
6 October 2025
Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy fo... |
| 26.09.2025 | European, Asian drugmaker shares drop after Trump imposes tariffs | European, Asian drugmaker shares drop after Trump imposes tariffs
By Gregor Hunter and Andrew SilverSeptember 26, 20256:58 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 The logo of... |
| 24.09.2025 | Immuto Scientific Secures $8M, Unlocks New Era in Precision Drug Discovery | Immuto Scientific, a biotechnology pioneer, has significantly advanced its mission. The company closed an oversubscribed $8 million Seed 2 financing round. This critical capital fuels its proprietary AI-enabled structural surfaceomics platf... |
| 22.09.2025 | Immuto Scientific: $8 Million Raised For Advancing New Class Of Therapeutic Targets With Structural Surfaceomics | Immuto Scientific has closed an oversubscribed Seed 2 financing round, raising a total of $8 million. The company has also announced a collaboration with Daiichi Sankyo, a well-known global pharmaceutical company. Immuto is utilizing its un... |
| 20.08.2025 | Australia stocks rise over 1%, crossing 9,000 threshold for the first time | Australian, Chinese and Indian stocks rose, while Japanese markets fell.
Australia’s S&P/ASX 200 benchmark crossed the 9,000 threshold for the first time.
India’s HSBC Composite flash purchasing managers’ index came in at 65.2, higher t... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 29.06.2025 | Japan’s Africa playbook has lessons for SEA founders | - |
| 24.06.2025 | Datroway: A New Dawn for Lung Cancer Treatment in the U.S. | In a significant leap for cancer treatment, Datroway has received approval in the United States for patients battling advanced EGFR-mutated non-small cell lung cancer (NSCLC). This milestone, achieved on June 24, 2025, marks a pivotal momen... |
| 24.06.2025 | Datroway: A New Dawn in Lung Cancer Treatment | In a world where cancer looms large, hope often flickers like a candle in the wind. But on June 24, 2025, a new light emerged with the approval of Datroway (datopotamab deruxtecan) in the United States. This innovative therapy targets advan... |
| 24.06.2025 | Datroway approved in US for EGFRm lung cancer | Datroway approved in US for EGFRm lung cancer
Tue, Jun 24, 2025 08:00 CET Report this content
24 June 2025
Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Based on TROPION-Lu... |
| 20.05.2025 | IHH Healthcare arm increases damages sought from Daiichi Sankyo to ₹11,800 crore over Fortis stake dispute | - |
| 20.05.2025 | Malaysia's IHH unit seeks up to $1.3 billion in damages from Japan's Daiichi Sankyo | IHH Healthcare said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi Sankyo over its Fortis Healthcare stake buy to up to 109.3 billion rupees ($1.28 billion).
Northern TK Venture (NTK)... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 08.02.2025 | IHH Healthcare's Legal Battle: A $1.25 Billion Gamble Against Daiichi Sankyo | In the world of healthcare, stakes can be high. For IHH Healthcare, the stakes just got even higher. The Malaysian healthcare giant is embroiled in a legal dispute with Japan's Daiichi Sankyo, seeking a staggering $1.25 billion in damages. ... |
| 07.02.2025 | IHH Healthcare’s damages against Daiichi could reach $1.25 billion, expert report says (Feb 6) | (Corrects Feb 6 story throughout to show the damages are according to an expert report, and not estimated by IHH's unit. The error also appeared in an earlier version of the story.)
(Reuters) -IHH Healthcare said on Thursday its unit submit... |
| 06.02.2025 | IHH Healthcare's unit seeks up to $1.25 billion from Japan's Daiichi over Fortis deal | Previous
FILE PHOTO: Daiichi Sankyo's company logo is pictured at its headquarters in Tokyo, Japan, October 20, 2023. REUTERS/Kim Kyung-Hoon/File photo
FILE PHOTO: The logo of IHH Healthcare Berhad (IHH) is seen at the Singapore Exchange be... |
| 06.02.2025 | IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says | Previous
FILE PHOTO: Daiichi Sankyo's company logo is pictured at its headquarters in Tokyo, Japan, October 20, 2023. REUTERS/Kim Kyung-Hoon/File photo
FILE PHOTO: The logo of IHH Healthcare Berhad (IHH) is seen at the Singapore Exchange be... |
| 25.12.2024 | AstraZeneca and Daiichi Sankyo Withdraw Lung Cancer Drug Application in EU: A Setback in Oncology Innovation | In a significant turn of events, AstraZeneca and Daiichi Sankyo have voluntarily withdrawn their marketing authorization application for datopotamab deruxtecan (Dato-DXd) in the European Union. This decision, announced on December 24, 2024,... |
| 24.12.2024 | Astra, Daiichi Withdraw EU Application for Lung Cancer Drug | (Bloomberg) -- AstraZeneca Plc and Daiichi Sankyo Co. have voluntarily withdrawn an application for a lung cancer treatment in the European Union in a blow for the experimental drug.
The two companies said Tuesday they had pulled the author... |
| 12.11.2024 | AstraZeneca and Daiichi Sankyo Forge Ahead with Datopotamab Deruxtecan Amid Regulatory Shifts | In the fast-paced world of oncology, AstraZeneca and Daiichi Sankyo are navigating the complex landscape of drug approval with their latest offering, datopotamab deruxtecan (Dato-DXd). This investigational drug is aimed at treating advanced... |
| 11.11.2024 | Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology | DAEJEON, South Korea, Nov. 11, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sa... |
| 31.10.2024 | The Future of Technology: Merging AI, Sustainability, and Innovation | In the bustling world of technology, two themes dominate the conversation: artificial intelligence (AI) and sustainability. Recent discussions at global forums reveal a clear vision for the future. Executives from leading companies are not ... |
| 31.10.2024 | “AI will acquire a human form,” top Nvidia executive tells Nikkei forum | Artificial intelligence “will acquire a human form,” a senior official at US chipmaker Nvidia told an event in Tokyo on October 28, while the CEO of Hyundai Motor said the South Korean automaker would create a “hydrogen ecosystem.”
The exec... |
| 23.09.2024 | Final OS results reported for TROPION-Breast01 | Final OS results reported for TROPION-Breast01
Mon, Sep 23, 2024 08:00 CET Report this content
23 September 2024
Datopotamab deruxtecan final overall survival results reported in
patients with metastatic HR-positive, HER2-low or negative br... |
| 03.09.2024 | SKIES ACROSS NORTH AMERICA TO LIGHT UP THIS FALL IN SUPPORT OF BLOOD CANCER PATIENTS | The Leukemia & Lymphoma Society kicks off philanthropic campaign Light The Night; communities nationwide encouraged to learn why awareness and support is critical
RYE BROOK, N.Y., Sept. 3, 2024 /PRNewswire/ -- The Leukemia & Lymphom... |
| 03.08.2024 | Tech Giants Stumble as Pharma Industry Rises in Germany | July 2024 was a month of turbulence for the tech giants. The once soaring market caps of companies like Alphabet and Microsoft took a nosedive. Investors, once enamored with the promise of artificial intelligence, began to question the sust... |
| 01.08.2024 | Germany Attracts Another Billion-Euro Pharma Project | French pharmaceutical giant Sanofi has confirmed it will invest 1.3 billion euros to expand insulin production in the western German city of Frankfurt am Main.
BERLIN, Aug. 1, 2024 /PRNewswire/ -- Sanofi says the expansion will encompass ar... |
| 01.07.2024 | Sanofi планирует инвестировать в Германию до $1,6 млрд | Как сообщила в понедельник газета Handelsblatt, Французская фармацевтическая компания Sanofi близка к принятию решения об инвестировании от €1,3 млрд до €1,5 млрд в крупную производственную площадку во Франкфурте, Германия, где она выпускае... |
| 18.06.2024 | Update on CAPItello-290 Phase III trial | Update on CAPItello-290 Phase III trial
Tue, Jun 18, 2024 08:00 CET Report this content
18 June 2024
Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy
in advanced or metastatic triple-negative breast cancer
The CAPIte... |
| 11.06.2024 | Japan biochemist who discovered statins, Akira Endo, dies | TOKYO: Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday (Jun 11).
Statins, which can prevent heart attacks or strokes, are among the most commonl... |
| 27.05.2024 | Dato-DXd improved OS in nonsquamous lung cancer | Dato-DXd improved OS in nonsquamous lung cancer
Mon, May 27, 2024 08:00 CET Report this content
This announcement contains inside information
27 May 2024
Datopotamab deruxtecan showed clinically meaningful overall survival
improvement vs. c... |
| 29.04.2024 | Enhertu improved PFS in HER2-low and ultralow | Enhertu improved PFS in HER2-low and ultralow
Mon, Apr 29, 2024 08:00 CET Report this content
29 April 2024
Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HE... |
| 25.04.2024 | 1st Quarter Results | 1st Quarter Results
Thu, Apr 25, 2024 08:00 CET Report this content
AstraZeneca
25 April 2024
Q1 2024 results
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Revenue and EPS summary
Q1 2024 % ... |
| 05.04.2024 | Imfinzi improved OS & PFS in limited-stage SCLC | Imfinzi improved OS & PFS in limited-stage SCLC
Fri, Apr 05, 2024 08:00 CET Report this content
05 April 2024
Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung ... |
| 02.04.2024 | FDA accepts Dato-DXd BLA for breast cancer | FDA accepts Dato-DXd BLA for breast cancer
Tue, Apr 02, 2024 08:00 CET Report this content
2 April 2024
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 12.03.2024 | Daiichi Sankyo Adopts Genedata Biologics to Automate the Discovery of Novel Biological Therapeutics | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Global leader in Biopharma R&D chooses the Genedata Biopharma Platform to ac... |
| 11.03.2024 | “ABEMA” original love program “Today, I fell in love. ” members Megan Natsukawa, Sono Hiramatsu, and Rei Mukai have been decided to participate in Loxonin (R) “Everyone’s Menstrual Pain Project for TE... | ABEMA
“ABEMA” original love program “Today, I fell in love. ” members Megan Natsukawa, Sono Hiramatsu, and Rei Mukai have been decided to participate in Loxonin (R) “Everyone’s Menstrual Pain Project for TEEN” as project members
Megan Natsu... |
| 14.12.2021 | Daiichi Sankyo : "R&D Day 2021" | Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma, Vice President, Corporat... |
| 29.10.2021 | Real-world evidence on Gilead's HIV combo Biktarvy confirms high efficacy; Digital therapeutics firm to trade on Nasdaq | Gilead on Friday announced interim results from an ongoing, real-world trial for its HIV drug Biktarvy, confirming its effectiveness in more than 1,100 people living with HIV, and analyzing patient-reported outcomes ... |
| 29.10.2021 | Alnylam’s John Maraganore isn’t the only CEO to leave his post; CRISPR’s chief commercial officer takes the helm at a protein degradation player | John Maraganore
The departure of a number of CEOs is the prevailing theme that kicks off this week’s installment: In a stunner, Alnylam CEO John Maraganore announced that Yvonne Greenstreet will be his successor at the end of ... |
| 29.10.2021 | FDA clears Pfizer's Covid-19 vaccine for children ages 5-11 | One of the latest additions to Vas Narasimhan’s “wild card” drug list has delivered.
Scemblix, as asciminib will be marketed, will be the first STAMP inhibitor approved for chronic myeloid leukemia, according to Novartis.
More specifically,... |
| 29.10.2021 | Is that drug ad for me? People pay more attention to pharma DTC for familiar conditions, study finds | Drug ads on TV are always telling people to “ask your doctor.” But guess what? Almost one in five actually do bring up a drug they’ve seen in advertising during a medical visit while one in 10 say they even ask directly for t... |
| 29.10.2021 | FDA clears Pfizer's Covid-19 vaccine for children ages 5-11 | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The busy IPO season shows no sign of slowing, with three more biotechs trick-or-treating for their own stock tickers and some s... |
| 29.10.2021 | Covid-19 roundup: Takeda preps rollout of Novavax shot for next year — report; G20 targets 70% world vaccination rate by mid-2022 | A couple days after Novavax filed for authorization of its Covid-19 vaccine in the UK, the company is reportedly plotting a Japanese rollout sometime next year.
Takeda, Novavax’s partner in Japan, is preparing to seek au... |
| 29.10.2021 | FDA clears Pfizer's Covid-19 vaccine for children ages 5-11 | Queen Latifah is done. With weight jokes, judgy people, self-hate and a complicit media. Novo Nordisk’s newest face — and body — for anti-obesity awareness lays out the struggles in a series of video vignettes that never even mention the wo... |
| 28.10.2021 | 'I want to be a granddad': Why John Maraganore left and where he (and Alnylam) are going | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| 11.08.2021 | Plain Language Results of DESTINY-Breast01 Clinical Study: CISCRP & OxfordPharmaGenesis Collaborate with Partners For Article in Future Oncology | The teams involved—Daiichi Sankyo, AstraZeneca, CISCRP, Oxford PharmaGenesis, and Dr. Modi —worked to ensure the PLSP was easy-to-read by adding creative visuals, tables and key questions answered about the DESTINY-Breast01 trial.
BOSTON (P... |
| 14.05.2021 | DAIICHI SANKYO COMPANY, LIMITED
Daiichi Sankyo : Announces the Introduction of a Trust-type Share-based Compensation System for its Directors, etc. | Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma, Vice President, Corporat... |
| 13.05.2021 | DAIICHI SANKYO COMPANY, LIMITED
Daiichi Sankyo : Announces Changes to Representative Directors, Directors and Audit & Supervisory Board Members | Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma, Vice President, Corporat... |
| 08.05.2021 | AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it's adding more heat under Gilead's Trodelvy | After the approval of their partnered anti-HER2 antibody-drug conjugate earlier this year, AstraZeneca and Daiichi Sankyo are riding high on the promise of their blooming partnership. Now a second ADC is showing promise in... |
| 01.04.2021 | Blocked by the EU's export ban, Japan got its first AstraZeneca vaccines from the US | A medical worker receives a dose of COVID-19 vaccine on March 5, 2021, in Tokyo.
Yoshikazu Tsuno - Pool/Getty Images
Japan received a cargo of AstraZeneca vaccine from the US, the company told local media Thursday.
Japan wanted to source do... |
| 01.04.2021 | Blocked by the EU’s export ban, Japan got its first AstraZeneca vaccines from the US instead | A medical worker receives a dose of COVID-19 vaccine on March 5, 2021, in Tokyo. Yoshikazu Tsuno – Pool/Getty Images
Japan received a cargo of AstraZeneca vaccine from the US, the company told local media Thursday.
Japan wanted to source do... |
| 01.04.2021 | Blocked by the EU's export ban, Japan got its first AstraZeneca vaccines from the US instead | A medical worker receives a dose of COVID-19 vaccine on March 5, 2021, in Tokyo. Yoshikazu Tsuno - Pool/Getty Images
Redeem now
Japan received a cargo of AstraZeneca vaccine from the US, the company told local media Thursday.
Japan wanted t... |
| 16.07.2019 | Celgene Exercises Commercial Option for Zymeworks’ Azymetric™ Platform Triggering $7.5MM Milestone Payment | VANCOUVER, British Columbia–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has sel... |
| 23.05.2019 | Daiichi Sankyo reportedly selling OTC unit for $900M in pivot to oncology — but company says it's 'incorrect' | Daiichi Sankyo has countered a news report that it’s looking to sell its over-the-counter subsidiary for about $900 million, once again dispelling speculation that’s been widely circulated as the drugmaker consolidates op... |
| 14.05.2019 | FDA expert panel questions Daiichi Sankyo leukemia drug data ahead of meeting | The ODAC’s questions focus on data from the Phase III QuANTUM-R trial, comparing quizartinib against salvage chemotherapy in FLT3-mutated patients. In particular, the briefing document questioned the credibility of the survival analysis of ... |
| 08.05.2019 | AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches | Buoyed by the performance of its oncology drugs, in March AstraZeneca chief Pascal Soriot bet big to partner with Daiichi Sankyo on its experimental breast cancer drug, with $1.35 billion upfront in a deal worth up to roug... |
| 16.04.2019 | LifeArc licenses lead stage molecules to Daiichi Sankyo | London UK, April 16, 2019: LifeArc, one of the UK’s leading medical research charities, has signed a deal to license an ion channel drug discovery programme to Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo).
Small molecules, o... |
| 02.04.2019 | Astellas’s Xospata in AML scores a goal with new Phase III survival data at AACR | Xospata received Food and Drug Administration approval in November based on earlier results from the same study, titled ADMIRAL, but that only showed the drug produced a complete remission with full or partial hematological recovery – known... |
| 29.03.2019 | Sunao Manabe takes top job at Daiichi Sankyo in wake of AstraZeneca deal; CAR-T player Celyad promotes Filippo Petti to CEO | Sunao Manabe
→ Barely a day after Daiichi Sankyo wrapped a mammoth collaboration deal with AstraZeneca, the Japanese pharma announced a succession plan for its CEO. George Nakayama, who’s keeping his chairman seat, is pass... |
| 08.05.2018 | Daiichi scores in PhIII study of AML drug, beating chemo and building its case for worldwide approvals | An AML drug picked up by Daiichi Sankyo in its Ambit buyout has outshone chemotherapy in a late-stage trial, setting up the Japanese drugmaker to file for worldwide approvals.
Antoine Yver
The drug, called quizartinib, was te... |
| 11.01.2017 | Daiichi Sankyo launches global R&D restructuring, looking to slash costs in an overhaul | You can add Japan’s Daiichi Sankyo to the list of pharma companies restructuring their R&D organizations.
Like Takeda before it and a whole lineup of US and European pharmas, Daiichi Sankyo is shuttering a research ... |
| 05.09.2016 | Beyond the pill: 5 ways to create value with patient-centric services | Shifts in regulations, technology and consumer expectations are triggering huge changes within the pharmaceutical industry. With an increased focus on patient outcomes, companies are looking to provide solutions that are patient-centric, ra... |
